Business Wire

SWEEP

25.5.2023 00:02:32 CEST | Business Wire | Press release

Share
Sweep Launches the First Tech Solution to Comply With Demanding EU Sustainability Disclosure Regulations

Sweep, the leading carbon and ESG management platform, today launched Sweep for Compliance, the first solution for reliable, transparent, and audit-ready reporting in compliance with the EU’s new Corporate Sustainability Reporting Directive (CSRD).

By 2025, an estimated 50,000 European Union businesses and at least 10,000 EU-based foreign companies will be falling under the scope of the CSRD, requiring them to communicate their 2024 extra-financial information. Globally, a rising number of sustainability disclosure regulations demand companies and financial institutions to track and publicly communicate new sets of data. If companies fail to act, they face compliance risks, such as financial sanctions, legal penalties, and damaging greenwashing accusations.

But, measuring ESG and carbon data is complex and time consuming without the right technology. Two-thirds (65%) of French business leaders believe their organization is not sufficiently prepared to meet ESG objectives, nor to fulfill regulatory requirements according to Workiva. Sweep for Compliance helps businesses easily comply with the right ESG, carbon, and regulatory disclosure requirements using advanced data analytics and reporting requirements directly embedded into the platform.

In 2023, data collection can’t be a bottleneck for companies to track and improve their positive impact. Monitoring extra financial data is now a crucial business issue as European sustainability regulations become more stringent. Sweep for Compliance gives CFOs, CSOs, and auditors the most advanced tools to measure carbon and ESG data and comply with upcoming legislation,” says Rachel Delacour, CEO and Cofounder at Sweep.

Sweep for Compliance streamlines the disclosure exercise, from data gathering and quality checks, traceability and monitoring, to generating insights and in-depth reports. With up to 50% time saved in the auditing process, it ensures consistent, verified, and compliant ESG and carbon data reporting in one click. It’s the only solution on the market to help companies get ready and stay on track with disclosure requirements.

With the growing number of sustainability regulations and stakeholder demands for transparency, companies are under pressure to accurately communicate their impact. By working with tech partners like Sweep, large organizations can streamline the collection, monitoring, and reporting of their non financial data in one single place,” says Jérémie Joos, Co-Head of ESG Center of Excellence at KPMG France.

Sweep is the trusted data partner for companies such as pet food giant Royal Canin and global leader in connected health company Withings. After launching Sweep for Supply Chain in February 2023, the company is committed to creating the best solutions for organizations to improve their ESG and carbon impact while avoiding non-compliance damages. That’s how they can lead – and thrive – in the future low carbon economy.

• • •

About Sweep

Sweep helps businesses track and act on their carbon and ESG data, so they can become Forever Companies.

The data-driven platform makes it easy to understand, manage, and report carbon emissions and ESG metrics. Powerful collaboration features and user-focused design empower staff and entire value chains to grow a sustainable business. And with all the data in one place, its advanced analytics offer comprehensive insights and deliver auditable reports aligned with the latest sustainability regulations and frameworks.

Sweep is B Corp certified and a member of the World Bank’s Carbon Pricing Leadership Coalition, France Invest, and The International Emissions Trading Association. It was selected to join FrenchTech Next 120/40 program and was named “Europe’s fastest growing scale up by Financial Times’ Sifted.

For more information, visit sweep.net

About KPMG France

KPMG in France – market leader in Audit and Consulting – is a 11,000-strong team of professionals dedicated to creating a new prosperity that's set to enhance companies of all sizes. In 2022, a century after its founding, KPMG became a "société à mission” (Purpose-driven company). Its purpose is to work and innovate with passion, to build trust, to combine performance and responsibility and to develop talent at the heart of the economy, territories and society. Thanks to its multidisciplinary model, KPMG combines industry, ESG and digital expertise by relying on its ESG Center of Excellence and its community of 1 000 digital experts to support the growth and transformation projects of its 100,000 clients all over the country.

For more information, visit kpmg.fr

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005716/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye